title: Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.
abstract: Enhanced endogenous interferon (IFN) stimulated gene (ISG) signature has been associated with nonresponsiveness to hepatitis C treatment using pegylated-IFNα (pegIFNα) and ribavirin (RBV) in human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. Using a proteomic approach, we identified high levels of IFNα receptor 2a (IFNαR2a) in the serum of null responders to pegIFNα/RBV. IFNαR2a inhibited antiviral activity of all formulations of IFNα in JFH/Huh7.5 cells. Furthermore, serum from null responders, but not from those who achieved sustained virologic response, suppressed IFN-signaling and ISG expression in IFNα-stimulated PBMCs of healthy donors in an IFNαR2a specific fashion. An IFNαR2a transgenic mice model (C57BL/6) was generated that had significantly higher levels of IFNαR2a in the serum than the controls (P=0.001). Total ISG expression in the lymph nodes was significantly higher compared to wild-type mice (P value=0.0016). In addition, IFITM1 and SP110 had significantly increased expression in the liver, IFITM1 and ISG15 in the lymph node, and ISG15 and PLSCR1 in the spleen (P value<0.05). The underlying mechanism of resistance to hepatitis C treatment may involve transsignaling of the JAK/STAT pathway by the sIFNαR2a-IFNα/β complex and result in the enhanced ISG signature observed in null responders. In this regard, the transgenic mice model simulated nonresponders to IFNα therapy and provides valuable insights into the role of sIFNαR2a-IFNα interactions in vivo.
authors.affiliation: 1 Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland.
authors.forename: Yu-Jin
authors.initials: YJ
authors.lastname: Lee
authors.forename: Xiaozhen
authors.initials: X
authors.lastname: Zhang
authors.forename: Estefania
authors.initials: E
authors.lastname: Vazquez
authors.forename: Gayathri
authors.initials: G
authors.lastname: Shivasabesan
authors.forename: Howard A
authors.initials: HA
authors.lastname: Young
authors.forename: Alison
authors.initials: A
authors.lastname: Murphy
authors.forename: Honghui
authors.initials: H
authors.lastname: Wang
authors.forename: Anthony F
authors.initials: AF
authors.lastname: Suffredini
authors.forename: Ulrich
authors.initials: U
authors.lastname: Siebenlist
authors.forename: Shyam
authors.initials: S
authors.lastname: Kottilil
mesh_terms: D000818:Animals; D060085:Coinfection; D006678:HIV / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D016174:Hepacivirus / Q000187:drug effects* / Q000276:immunology; D006526:Hepatitis C / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D053633:Receptor, Interferon alpha-beta / Q000097:blood / Q000276:immunology*; D012254:Ribavirin / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology
chemical_list: C508033:IFNAR2 protein, human; D016898:Interferon-alpha; D053633:Receptor, Interferon alpha-beta; D012254:Ribavirin